Back to top
more

AstraZeneca (AZN)

(Real Time Quote from BATS)

$77.77 USD

77.77
1,404,313

+1.10 (1.44%)

Updated Jul 10, 2024 01:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Pfizer Ibrance sNDA Accepted by FDA under Priority Review

Pfizer Inc.'s (PFE) supplemental new drug application (sNDA) to convert accelerated approval for its breast cancer drug, Ibrance, to regular approval was accepted by the FDA under priority review.

    Clovis Scales 52-Week High on Early FDA Nod for Rubraca

    Shares of Clovis Oncology (CLVS) touched a 52-week high after the company gained accelerated FDA nod for its advanced ovarian cancer drug, Rubraca.

      Ionis (IONS) Receives Milestone Payment from AstraZeneca

      Ionis (IONS) received $28 million from AstraZeneca (AZN) following the completion of IND-supporting studies and licensing of IONIS-KRAS-2.5.

        Alexion Slips to 52-Week Low as CEO, CFO Quit amid Probe

        Alexion's (ALXN) shares plunged after the company's board of directors announced new leadership appointments.

          Biogen Presents Positive Early Data from Alzheimer's Study

          Last week, Biogen Inc. (BIIB) presented positive data from a phase I study (PRIME) on its anti-amyloid treatments in development, aducanumab, at the Clinical Trials on Alzheimer's Disease (CTAD) meeting in San Diego.

            Lilly/AstraZeneca Expand Alzheimer Disease Collaboration

            Eli Lilly and Company (LLY) and AstraZeneca plc (AZN) expanded their existing collaboration to develop the second treatment for Alzheimer's disease, MEDI1814

              Arpita Dutt headshot

              Pharma Stock Roundup: Drug Pricing Heat Back on Sector, Endo, Mylan, AZN to Cut Jobs

              Drug pricing is back in focus with president-elect Trump making it clear that he does not like price increases.

                AstraZeneca (AZN) Presents Tagrisso Data at Medical Meeting

                AstraZeneca plc (AZN) presented positive data from a randomized phase III study (AURA3) on its lung cancer drug Tagrisso at a lung cancer conference in Vienna, Austria.

                  Sheraz Mian headshot

                  Top Research Reports for Cisco, Merck & MasterCard

                  Today's Research Daily features new research reports on 16 major stocks, including MasterCard (MA), Merck (MRK) and Cisco (CSCO).

                    Arpita Dutt headshot

                    Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytruda

                    This week, companies like Merck (MRK) and Pfizer (PFE) provided updates on their pipelines.

                      Eric Dutram headshot

                      Is Immunotherapy the Next Hot Industry for Biotech Stock Investors?

                      In this edition of the Dutram Report, Eric Dutram talks with Brad Loncar, the CEO of Loncar Investments who specializes in the world of immunotherapy. This approach is revolutionizing the cancer treatment market, and we get to the bottom of this emerging technology in the podcast so that investors can better understand why this market may deserve a closer look.

                        Mark Vickery headshot

                        Argument for Interest Rate Hike "Quite Strong"

                        Fed Vice Chair Stanley Fischer said he is optimistic a rate hike would be manageable abroad, and that a stronger U.S. economy should help other countries.

                          Tracey Ryniec headshot

                          Is Brexit a Buying Opportunity?

                          Value investors should keep an eye on what is going on in Great Britain right now.

                            Mark Vickery headshot

                            Market News Over Summer Vacation: PFE, AZN, TSLA, LZB

                            You know you're in a slow news cycle when the market focus is on a Janet Yellen speech that doesn't happen until Friday, and no one expects any action to come of it anyway.

                              Brian Bolan headshot

                              Low PE Stocks For This Market

                              A look at four stocks with low PE's and earnings estimate revisions that are among the best over the last four weeks.

                                Arpita Dutt headshot

                                Pharma Stock Outlook: Let's Make a Deal

                                M&As continue to play a major role in the pharma and biotech sector and are not showing any signs of slowing down.

                                  Arpita Dutt headshot

                                  Pharma Stock Outlook: Let's Make a Deal

                                  M&As continue to play a major role in the pharma and biotech sector and are not showing any signs of slowing down.